Trial
NCT02604199
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Arrowhead Pharmaceuticals
Collaborators
—
Condition
Hepatitis B
Intervention
ARC-520 Injection
Why stopped
Company decision to discontinue trial
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-13